S
SABS
vs
S&P 500
S&P 500
Over the past 12 months, SABS has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's +14% growth.
Stocks Performance
SABS vs S&P 500
Performance Gap
SABS vs S&P 500
Performance By Year
SABS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
SAB Biotherapeutics Inc
Glance View
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Sioux Falls, South Dakota and currently employs 139 full-time employees. The company went IPO on 2021-01-12. The firm offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The firm is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.